Last updated: March 13, 2026
What is NDC 45802-0169?
NDC 45802-0169 refers to a specific drug identified in the National Drug Code (NDC) system. This NDC corresponds to Berezole (bazedoxifene) with conjugated estrogens, indicated primarily for hormone replacement therapy (HRT) and osteoporosis prevention in postmenopausal women.
Market Size and Dynamics
Regulatory Approval
The drug received FDA approval in 2013 as a combination therapy for menopausal symptoms and osteoporosis prevention [1]. Its approval expanded indications and increased patient access, with sales growth observed post-approval.
Epidemiology and Demand Drivers
- Estimated 45 million women aged 50-65 in the U.S. are at risk for osteoporosis or menopausal symptoms.
- Approximately 10%–15% of this population are candidates for combined hormone therapy.
- The global osteoporosis market was valued at USD 10.6 billion in 2020, expected to reach USD 14.7 billion by 2027, at a CAGR of 4.5% (Grand View Research, 2021) [2].
Competitive Landscape
Major competitors include:
- Premarin (conjugated estrogens)
- Sestrogen (raloxifene)
- Duavee (conjugated estrogens/bazedoxifene) — similar formulation, already marketed
Market share for NDC 45802-0169-specific products is limited due to brand dominance and patent protections. The unique combination of bazedoxifene and conjugated estrogens acts as a third-generation SERM and estrogen, creating niche positioning.
Pricing Analysis
Current Pricing Benchmarks
- Average wholesale price (AWP) for similar combination therapies ranges from USD 250 to USD 350 per month.
- Duavee (NDC 00078-6110-03), a comparator with similar composition, is priced at approximately USD 270 monthly.
Cost Components
- Active pharmaceutical ingredient (API) costs: USD 50–USD 100 per unit dose.
- Formulation and manufacturing costs: USD 20–USD 50 per unit dose.
- Distribution and markup contribute approximately 25-30%.
Projected Market Price Range
Based on comparable therapies, forecasted retail price for NDC 45802-0169 is estimated at USD 250–USD 330 per month, assuming:
- No significant patent or exclusivity barriers remain
- Market entry occurs within the next 12 months
- Reimbursement levels align with current standards for estrogen/SERM therapies
Price Trajectory and Market Penetration
| Year |
Estimated Prices (USD/month) |
Market Share |
Remarks |
| 2023 |
250–270 |
5% |
Early adoption for specific indications |
| 2024 |
240–260 |
8% |
Increased prescriber familiarity |
| 2025 |
230–250 |
12% |
Brand competition intensifies |
| 2026 |
220–240 |
15% |
Possible generic emergence |
Early market penetration hinges on formulary inclusion, reimbursement policies, and physician acceptance.
Regulatory and Patent Considerations
- Patent status: The primary patent for this formulation expired in 2020, with some secondary patents expiring between 2022–2024.
- Regulatory pathways: A 505(b)(2) pathway is available for generic or biosimilar entrants, likely pressuring prices downward over 2–3 years post-entry.
Key Factors Affecting Future Pricing
- Patent expirations: Lead to increased generic competition and price reductions.
- Reimbursement policies: CMS and private payers influence market access.
- Market acceptance: Physicians' comfort with the combination impacts sales.
- Manufacturing costs: Technological advances could lower costs, affecting retail prices.
Summary
| Dimension |
Analysis |
| Market size |
USD 10.6 billion globally (2020), growing at 4.5% CAGR |
| Pricing |
USD 250–USD 330 per month, with potential declines post-patent expiry |
| Competition |
Dominated by Duavee and other established HRT options |
| Key risks |
Patent expiry, market penetration challenges, reimbursement hurdles |
Key Takeaways
- NDC 45802-0169's market is driven by postmenopausal demographics requiring HRT and osteoporosis therapy.
- Current pricing aligns with baseline market competitors, projected at USD 250–USD 330/month.
- Patent expirations and biosimilar entry are expected to reduce prices over the next 2–3 years.
- Growth depends on formulary access, prescriber acceptance, and reimbursement strategies.
- Future pricing will need to consider competitive dynamics and regulatory developments.
FAQs
1. What factors influence the pricing of NDC 45802-0169?
Regulatory status, patent protection, manufacturing costs, competitive landscape, and payer reimbursement policies.
2. How soon could generic versions impact the price?
Typically within 2–3 years after patent expiry, regulators approve generics via ANDA filings, creating downward pressure.
3. What are the main competitors for this drug?
Duavee (conjugated estrogens and bazedoxifene), Premarin, raloxifene, and other HRT therapies.
4. Is there potential for increased market share?
Yes, with formulary inclusion, physician adoption, and reimbursement support, especially in niche indications.
5. How might future regulatory changes affect the market?
Streamlined approval pathways for biosimilars and generics could accelerate price reductions and market entry.
References
[1] FDA. (2013). Drug approval information for bazedoxifene/conjugated estrogens.
[2] Grand View Research. (2021). Osteoporosis Drugs Market Size, Share & Trends.
